Ranbaxy UK in generic drugs price row
Ranbaxy UK and Generics UK, respective subsidiaries of India's RanbaxyLaboratories and Germany's Merck KGaA, are facing legal action brought by the UK authorities for allegedly overcharging the National Health Service on sales of the antiulcer agent ranitidine, following a raid on the former's London offices by the Serious Fraud Office.
The NHS, in its submission to the court, has said that it was deprived of at least L100 million ($183 million), and possibly L110 million, from the over-pricing of the drug and that unlawful behavior took place in the middle to late 1990s.
Ranbaxy has confirmed receipt of the claim and has, in response, stated that "the company is not aware of any wrongdoing and will defend vigorously legal proceedings (if served)." Cumulative sales of Ranbaxy in the UK, for all products between 1997 and 2000 amounted to L35 million and L48 million last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze